Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2018 August;66(4) > Minerva Cardioangiologica 2018 August;66(4):508-17

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Cardioangiologica 2018 August;66(4):508-17

DOI: 10.23736/S0026-4725.18.04641-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Magic Touch®: preliminary clinical evidence with a novel sirolimus drug coated balloon

Bernardo CORTESE 1, 2 , Gaetano DI PALMA 1, 3, Roberto LATINI 1

1 ASST Fatebenefratelli-Sacco, Milan, Italy; 2 Monasterio Foundation, Tuscany Region, CNR, Pisa, Italy; 3 Unit of Cardiology, Second University of Naples, Naples, Italy


PDF


Drug-coated balloons (DCB) have been developed in recent years to overcome some of the drug-eluting stents limitations. There is an established indication for the use of DCB in the treatment of in-stent restenosis and they are also variably used in various setting, in particular small coronary vessels and bifurcations. Until 2016, all DCBs available in Europe eluted paclitaxel, a highly lipophilic drug with narrow therapeutic window. In April 2016 a new sirolimus-coated balloon (Magic Touch®, Envision Scientific PVT, Bhatpore, India) obtained the CE Mark. This device shares a new-generation delivery system and is able to release in a few seconds an effective dosage of sirolimus.


KEY WORDS: Drug-eluting stents - Sirolimus - Coronary artery disease

inizio pagina